We could not find any results for:
Make sure your spelling is correct or try broadening your search.
By Peter Loftus Gilead Sciences Inc. (GILD) has discontinued development of a treatment for a rare lung disease after it failed to meet its efficacy goal in a clinical trial. The drug...
CHICAGO, Oct. 19 /PRNewswire/ -- Seven Summits Strategic Investments releases its Stocks To Watch Guide. The Seven Summits Strategic Investments Stocks To Watch Guide (go to:...
Boeing Co. (BA), DuPont Co. (DD), Pfizer Inc. (PFE) and Microsoft Corp. (MSFT) are among the major companies posting quarterly results next week. Meanwhile, economic reports are expected to show...
CHICAGO, Oct. 5 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for X, GILD, DOW, BBD, and MVL. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
By Carla Mozee Biotech firm Gilead Sciences Inc. (GILD) said Friday that it has received a subpoena from the U.S. Department of Health and Human Services requesting documents about the...
By Nick Godt With any concerns about the second-quarter earnings season mostly behind, the market will now key on more signs of "green shoots" in big economic reports, starting with the...
Gilead Sciences Inc.'s (GILD) second-quarter profit climbed 31% on strong sales of its core HIV treatment franchise, but its disappointing revenue outlook sent shares lower. The Foster City...
Gilead Sciences Inc. (GILD) raised its projection for 2009 net product revenue to $6.1 billion to $6.2 billion in its first update since April's $1.4 billion acquisition of CV Therapeutics. The...
Gilead Sciences Inc.'s (GILD) second-quarter profit climbed 31% as the biopharmaceutical company reported higher sales from its HIV products and added revenue from its acquisition of heart-drug...
Gilead Sciences Inc. (GILD) said on Thursday it filed a lawsuit against Israeli-based Teva Pharmaceutical Industries Inc. (TEVA) and its U.S. subsidiary for infringement of two patents tied to two...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions